■针对干燥综合征(SS)的靶向治疗已成为临床医生的重要关注点。多组学广泛的孟德尔随机化(MR)分析为识别潜在的药物靶标提供了新思路。
■我们进行了基于汇总数据的孟德尔随机化(SMR)分析,以通过整合DNA甲基化来评估与SS相关的治疗靶标,基因表达和蛋白质数量性状基因座(mQTL,eQTL,和pQTL,分别)。与SS的遗传关联来源于FinnGen研究(发现)和GWAS目录(复制)。采用共定位分析来确定两种潜在相关表型在给定区域中是否共享相同的遗传因素。此外,深入研究DNA甲基化之间的潜在调控,基因表达,和蛋白质丰富,我们进行了MR分析,以探讨候选基因甲基化与表达之间的因果关系,以及基因表达和蛋白质丰度之间。进一步采用药物预测和分子对接来验证候选药物靶标的药理活性。
■在整合多组数据后,我们确定了与SS风险相关的三个基因:TNFAIP3,BTN3A1和PLAU.BTN3A1中cg22068371的甲基化与蛋白水平呈正相关,与cg22068371甲基化对SS风险的负面影响一致。此外,PLAU(cg04939496)基因甲基化与表达呈正相关,以及表达和蛋白质水平之间。这种一致性阐明了PLAU在DNA甲基化时对SS风险的促进作用,基因表达,和蛋白质水平。在蛋白质水平,遗传预测的TNFAIP3(OR2.47,95%CI1.56-3.92)与SS风险呈正相关,而BTN3A1(OR2.96E-03,95%CI2.63E-04-3.33E-02)与SS风险呈负相关。分子对接显示候选药物和靶蛋白的稳定结合。
■我们的研究揭示了治疗SS的有希望的治疗目标,为SS的靶向治疗提供有价值的见解。然而,有必要通过未来的实验进一步验证.
UNASSIGNED: Targeted therapy for Sjögren\'s syndrome (SS) has become an important focus for clinicians. Multi-omics-wide Mendelian randomization (MR) analyses have provided new ideas for identifying potential drug targets.
UNASSIGNED: We conducted summary-data-based Mendelian randomization (SMR) analysis to evaluate therapeutic targets associated with SS by integrating DNA methylation, gene expression and protein quantitative trait loci (mQTL, eQTL, and pQTL, respectively). Genetic associations with SS were derived from the FinnGen study (discovery) and the GWAS catalog (replication). Colocalization analyses were employed to determine whether two potentially relevant phenotypes share the same genetic factors in a given region. Moreover, to delve deeper into potential regulation among DNA methylation, gene expression, and protein abundance, we conducted MR analysis to explore the causal relationship between candidate gene methylation and expression, as well as between gene expression and protein abundance. Drug prediction and molecular docking were further employed to validate the pharmacological activity of the candidate drug targets.
UNASSIGNED: Upon integrating the multi-omics data, we identified three genes associated with SS risk: TNFAIP3, BTN3A1, and PLAU. The methylation of cg22068371 in BTN3A1 was positively associated with protein levels, consistent with the negative effect of cg22068371 methylation on the risk of SS. Additionally, positive correlations were observed between the gene methylation of PLAU (cg04939496) and expression, as well as between expression and protein levels. This consistency elucidates the promotional effects of PLAU on SS risk at the DNA methylation, gene expression, and protein levels. At the protein level, genetically predicted TNFAIP3 (OR 2.47, 95% CI 1.56-3.92) was positively associated with SS risk, while BTN3A1 (OR 2.96E-03, 95% CI 2.63E-04-3.33E-02) was negatively associated with SS risk. Molecular docking showed stable binding for candidate drugs and target proteins.
UNASSIGNED: Our study reveals promising therapeutic targets for the treatment of SS, providing valuable insights into targeted therapy for SS. However, further validation through future experiments is warranted.